202 related articles for article (PubMed ID: 30148829)
41. Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.
Pandya C; Hashmi S; Khera N; Gertz MA; Dispenzieri A; Hogan W; Siddiqui M; Noyes K; Kumar SK
Clin Transplant; 2014 Oct; 28(10):1084-91. PubMed ID: 25040732
[TBL] [Abstract][Full Text] [Related]
42. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
43. Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma.
Blix ES; Kildal AB; Bertelsen E; Waage A; Myklebust JH; Kolstad A; Husebekk A
Biol Blood Marrow Transplant; 2015 May; 21(5):840-7. PubMed ID: 25689789
[TBL] [Abstract][Full Text] [Related]
44. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Jakubowiak AJ; McCarthy PL; Orlowski RZ; Attal M; Bladé J; Goldschmidt H; Weisel KC; Ramasamy K; Zweegman S; Spencer A; Huang JSY; Lu J; Sunami K; Iida S; Chng WJ; Holstein SA; Rocci A; Skacel T; Labotka R; Palumbo A; Anderson KC
Blood Cancer J; 2020 Feb; 10(2):17. PubMed ID: 32054831
[TBL] [Abstract][Full Text] [Related]
45. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
46. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R; Muchtar E; Kumar S; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2017 Jan; 52(1):34-40. PubMed ID: 27548464
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
48. Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.
Khouri J; Majhail NS
Curr Opin Support Palliat Care; 2017 Dec; 11(4):361-365. PubMed ID: 28922292
[TBL] [Abstract][Full Text] [Related]
49. Stem Cell Transplantation in Multiple Myeloma.
Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
[TBL] [Abstract][Full Text] [Related]
50. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
[TBL] [Abstract][Full Text] [Related]
51. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies.
Parrondo RD; Ailawadhi S; Sher T; Chanan-Khan AA; Roy V
JCO Oncol Pract; 2020 Feb; 16(2):56-66. PubMed ID: 32045556
[TBL] [Abstract][Full Text] [Related]
52. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
[TBL] [Abstract][Full Text] [Related]
53. Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.
Kamber C; Zimmerli S; Suter-Riniker F; Mueller BU; Taleghani BM; Betticher D; Zander T; Pabst T
Bone Marrow Transplant; 2015 Apr; 50(4):573-8. PubMed ID: 25599166
[TBL] [Abstract][Full Text] [Related]
54. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
55. What is the role of autologous transplant for lymphoma in the current era?
Stiff P
Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
[TBL] [Abstract][Full Text] [Related]
56. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F
Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
[TBL] [Abstract][Full Text] [Related]
57. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
[TBL] [Abstract][Full Text] [Related]
58. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
59. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT.
Garderet L; Morris C; Beksac M; Gahrton G; Schönland S; Yakoub-Agha I; Hayden PJ
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1559-1566. PubMed ID: 32417491
[TBL] [Abstract][Full Text] [Related]
60. Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis.
Mair M; Straka C; Buratti T; Tauber M; Mitterer M; Fong D
Ann Hematol; 2020 May; 99(5):1031-1040. PubMed ID: 32140891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
